Simon, Audrey <br/><br/>
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.  [electronic resource] 

 -  British journal of haematology  Oct 2010 
 - 159-66 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2010.08329.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bleomycin--administration & dosage<br/>Cisplatin--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Dacarbazine--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Etoposide--administration & dosage<br/>Female<br/>Humans<br/>Ifosfamide--administration & dosage<br/>Lymphoma, T-Cell, Peripheral--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Prednisone--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome<br/>Vinblastine--administration & dosage<br/>Vincristine--administration & dosage<br/>Young Adult